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Tuberculosis  (TB) is as old as the mankind1-3.
TB is  the  most  common cause of death due to a
single  infectious agent  worldwide  in  adults4. In
1993, the World Health Organization (WHO) took
an unprecedented step and declared TB to be a global
emergency4-6. According to the recent estimates, one-
third of the human population (about 1.86 billion
people) was infected with  Mycobacterium
tuberculosis worldwide in 19977 . TB is principally
a disease of poverty, with 95 per cent of cases and 98
per cent of deaths occurring in developing countries.
Of these, more than half the cases occur in five South-
East Asian countries7. In 1997, nearly 1.87 million
people died of TB and the global case fatality rate
was 23 per cent. This figure exceeded 50 per cent in
some of the African countries where human
immunodeficiency virus (HIV) is highly prevalent7.
It is estimated that between 2002 and 2020,
approximately 1000 million people will be newly
infected, over 150 million people will get sick, and
36 million will die of TB if proper control measures
are not instituted4.
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Multidrug-resistant tuberculosis  (MDR-TB) caused by Mycobacterium tuberculosis resistant to
both isoniazid and rifampicin  with or without resistance to other drugs is among the most
worrisome elements of the pandemic of antibiotic resistance.   Globally, about three per cent of
all newly diagnosed patients have MDR-TB. The proportion is higher in patients who have
previously received antituberculosis treatment reflecting the failure of programmes designed
to ensure complete cure of patients with tuberculosis.  While host genetic factors may probably
contribute, incomplete and inadequate treatment is the most important factor leading to the
development of MDR-TB.  The definitive diagnosis of MDR-TB is difficult in resource poor low
income countries because of non-availability of  reliable laboratory facilities.  Efficiently run
tuberculosis control programmes based on directly observed treatment, short-course (DOTS)
policy is essential for preventing the emergence of MDR-TB. Management of MDR-TB is a
challenge which should be undertaken by experienced clinicians at centres equipped with  reliable
laboratory service for mycobacterial culture and  in vitro sensitivity testing as it requires
prolonged use of expensive second-line drugs with a significant potential for toxicity. Judicious
use of drugs, supervised individualised treatment, focussed clinical, radiological and
bacteriological follow up, use of surgery at the appropriate juncture are key factors in the
successful management of these patients.  In certain areas, currently available programme
approach may not be adequate and innovative approaches such as DOTS-plus may have to be
employed to effectively control MDR-TB.
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Though the disease was known since ancient
times, the organism causing TB was described only
a century  ago by Robert Koch on 24th March 18823.
Until middle of the 20th century, there was no
definitive treatment available for TB. With the
availability streptomycin, isoniazid  and para-
aminosalicylic acid (PAS), in the mid 1940s,
predictable, curative treatment for  TB became a
reality2.  The  introduction of  rifampicin,
pyrazinamide and ethambutol in the subsequent years
ushered in the era of short-course treatment. Further,
the fully supervised  sanatorium based  treatment  of
the earlier days also gave way  to  the totally
unsupervised  domiciliary  treatment.  Soon, it was
felt that TB could be  easily contained  and  possibly
eradicated.  The advent of HIV infection, the acquired
immunodeficiency syndrome (AIDS) pandemic in the
1980s1,8,9, struck a blow to this optimism and there
has been a global resurgence of TB. Strains of  M.
tuberculosis  resistant to both isoniazid and
rifampicin  with or without resistance to other drugs
have been termed multidrug-resistant strains.
Multidrug-resistant tuberculosis (MDR-TB) is among
the most worrisome elements of the pandemic of
antibiotic resistance because TB patients that fail
treatment have a high risk of death10-14.
RATIONALE FOR STRICT DEFINITION
Isoniazid, the most powerful mycobactericidal
drug available, ensures early sputum conversion  and
helps in decreasing the transmission of TB.
Rifampicin, by its mycobactericidal  and sterilising
activities is crucial for preventing relapses. Thus,
isoniazid and rifampicin are keystone drugs in the
management of TB. While resistance to either
isoniazid  or rifampicin may be managed with other
first-line drugs, resistance to both isoniazid and
rifampicin (MDR-TB) demands treatment with
second-line drugs. These drugs  have limited
sterilising capacity and are not suitable for short-
course treatment. Thus, patients with MDR-TB
require prolonged  treatment with  drugs that are less
effective and  more toxic. Therefore, it is necessary
to distinguish MDR-TB from  mere drug-resistant
tuberculosis by performing mycobacterial culture and
sensitivity testing because the therapeutic
implications are different.
It is possible to strictly define a  given isolate of
M.tuberculosis as multidrug-resistant only after
performing mycobacterial culture and in vitro
sensitivity  testing. Under programme conditions,
these facilities are usually not available and patients
are labelled as “treatment failure”, “re-treatment
failure”  and  “chronic cases”  as per the guidelines
issued by the WHO15. It is likely that several of these
patients may be excreting multidrug-resistant
organisms.  Keeping these facts in mind, the term
MDR-TB has been used in this review in the strict
sense of the definition referring to isolates resistant
to both isoniazid and rifampicin with or without
resistance to other drugs.
TERMINOLOGY OF DRUG RESISTANCE
Primary  resistance is that which has not resulted
from  the   treatment  of  the  patient  with  the  drug
concerned.   It    includes   resistance in wild strains
which have never come  into contact with  the drug
(natural resistance)  and  the resistance occurring as
a result of exposure  of  the strain to the drug but in
another patient.   Initial  resistance is the resistance
in patients who give  a history of never having
received chemotherapy in the past. It  includes
primary   resistance   and  resistance   to   previous
treatment concealed by the patient or of which the
patient was  unaware16,17.
The term “acquired  resistance” has often been
used with the implication that resistance has
developed due to exposure  of  the strain  to
antituberculosis drugs and the  consequent selecting
out  of  resistant mutant bacilli.  However, some of
the drug-resistant isolates in  previously treated
patients may actually represent primary resistance
among patients who remain uncured18,19. In the strict
sense, the term “acquired resistance” can be used to
refer to strains proven to have drug resistance in a
reliable laboratory which were subsequently isolated
from a patient in whom initial susceptibility testing
was done to document the presence of a drug
susceptible strain earlier18,19.  If initial drug
susceptibility testing has not been done, the term
“resistance among previously treated patients” would
be a more appropriate term than “acquired drug
resistance” 18,19. Susceptible strains are those that have
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not been exposed to  the   main antituberculosis drugs
and respond to these  drugs in a uniform manner.
Resistant strains differ from the sensitive strains in
their  capacity to grow in the presence of higher
concentration of a drug. Wild  strains  are  those that
have never  been  exposed  to antituberculosis drugs.
Naturally resistant strains are wild strains resistant
to  a drug  without having been in contact with it.  It
is  species specific and has been used as a taxonomic
marker16,17.
EPIDEMIOLOGY
World
Though studies published from the developing
world  suggested that drug resistance was a potential
problem20,21, it was the emergence of MDR-TB  in
USA in the 1990s which attracted the attention22,23.
The global extent of the problem of drug-resistant
tuberculosis is evident in the report by the WHO-
International Union Against Tuberculosis  and Lung
Disease (IUATLD) Global Project on Anti-
tuberculosis Drug Resistance Surveillance between
1994 and 1997 which described the prevalence of
resistance to four first-line antituberculosis drugs in
35 countries24.  In this study24, resistance to
antituberculosis drugs was found in all 35 countries
surveyed suggesting that it is a global problem. The
prevalence of acquired resistance to any drug ranged
from 5.3 per cent  in New Zealand  to 100 per cent
in Ivanovo Oblast, Russian Federation, with a median
value of 36 per cent. Resistance to all four drugs
among previously treated patients was reported in a
median of 4.4 per cent of the cases (range 0-17%).
The median prevalence of acquired MDR-TB was 13
per cent, with a range of 0 per cent (Kenya) to 54.4
per cent (Latvia). There are several “hot spots” around
the world where MDR-TB prevalence is high and
could threaten control programmes24. These include
Estonia, Latvia and  two Russian oblasts (territories)
in Europe; Argentina and the Dominican Republic
in the Americas; and Côte d’Ivoire in Africa.
This survey did not include temporal changes in
the prevalence of resistance. Further, in some
countries with high burden of TB, such as China,
India, and Russia, surveys were conducted only in
one administrative unit if, any and this was not
representative of the national  scenario. Therefore
WHO-IUATLD survey24 was extended to define this
problem further25. Between 1996 and 1999, patients
in 58 geographic sites were surveyed25. For newly
diagnosed patients, the frequency of resistance to at
least one antituberculosis drug ranged from 1.7 per
cent in Uruguay to 36.9 per cent in Estonia (median,
10.7%). The median prevalence of MDR-TB among
new cases of tuberculosis was only 1.0 per cent, but
the prevalence was much higher in Estonia (14.1%),
Henan Province in China (10.8%), Latvia (9%), the
Russian oblasts of Ivanovo (9%) and Tomsk (6.5%),
Iran (5%), and Zhejiang Province in China (4.5%).
A significant decrease  in multidrug resistance was
observed in France and the United States. In Estonia,
the prevalence in all cases increased from 11.7 per
cent in 1994  to 18.1 per cent in 199825. Results of
resistance surveys from 64 countries, together with
data predictive of resistance rates from 72 others
suggest that an estimated 273,000 new cases of MDR-
TB occurred worldwide in 2000 and constituted  3.2
per cent of all new TB cases26.
India
Reliable data on  the  epidemiology  of  MDR-TB
are lacking from India1. Though the problem of drug
resistance was observed in the early studies from
India20,21, resistance to both isoniazid and rifampicin
has been a recent phenomenon. It is felt that the
phenomenon of MDR-TB is on the  rise and is bound
to reach much more menacing proportions27-44.
In India, prevalence of primary MDR-TB in newly
diagnosed cases has been observed to be 3.4 per cent
or less (Table I). Data meticulously collected at the
Tuberculosis Research Centre (TRC), Chennai over
the last three decades suggest that rifampicin
resistance started appearing in the early 1990s and
MDR-TB levels in newly diagnosed patients has been
one  per cent or less36.
Prevalence of MDR-TB among previously treated
patients has been observed to be higher. In a study
conducted at a referral tuberculosis hospital in
Amargadh, Gujarat28,  multidrug resistance in
previously treated cases was observed to increase
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from 25.2 per cent in 1983 (n=305) to 33.8 per cent
in 1986 (n=260).  In the North Arcot district, between
1988-89, six per cent of the 3357 patients initiated
on antituberculosis treatment were found to have
MDR-TB29. More recently, in a study from Gujarat
44
, the patterns of  drug resistance were studied among
previously treated tuberculosis patients who remained
symptomatic or smear-positive despite receiving
antituberculosis drugs under the DOTS  programme
for a minimum period of five months. Of the 1472
patients studied, 804 (54.6%) were treatment failure
cases and 668 (45.4%) were relapse cases; 822
patients (373 failure and 449 relapse) were culture-
positive. Of these 822 patients, 482 (58.6%, 261
failure and 221 relapse) were resistant to one or more
drugs. Resistance to rifampicin and isoniazid with
or without resistance to other drugs was seen in 289
of the 822 patients (35.2%). However, caution has to
be exercised in interpreting the prevalence figures
published in studies with a small sample size because
of inherent methodological concerns.
The global epidemic of HIV infection/AIDS
Neville et al45 described  the  emergence   of   drug-
resistant  TB  as  the third epidemic. It is generally
accepted that patients with HIV infection/AIDS are at a
greater risk of developing TB8,18,22,23,46. In persons with
HIV infection/AIDS, factors such as increased
vulnerability, increased opportunity to acquire TB (due
to over crowding, exposure to patients with  MDR-TB,
increased hospital visits), and malabsorption of
antituberculosis drugs resulting in suboptimal therapeutic
blood levels inspite of strict adherence to treatment
regimen have all been postulated as the possible causes
for increased risk of acquiring  MDR-TB. Data from
published literature also support this view18,22,23,47,48.
BIOLOGIC AND MOLECULAR BASIS OF
DRUG RESISTANCE
Spontaneous chromosomally borne mutations
occurring in M. tuberculosis at a predictable rate is
Table I. Prevalence of multidrug resistant M. tuberculosis isolates among new cases in India
Place Study period No. of isolates tested Resistance to isoniazid and
rifampicin with or without
resistance to other drugs  (%)
Gujarat28 1983-86 570 0
North Arcot district29 1985-89 2779 1.6
Pondicherry region29 1985-91 2127 0.7
Bangalore30 1980s 436 1.1
Bangalore31 1985-86 588 1.4
Kolar31 1987-89 292 3.4
Jaipur33 1988-91 1009 0.8
Tamil Nadu state35 1997 384 3.4
Composite North Arcot district*43 1999 282 2.8
Composite Raichur district†43 1999 278 2.5
*North Arcot district in Tamil Nadu state has now been split into two  smaller districts. Composite North Arcot district refers to
these two smaller districts Vellore and Tiruvannamalai
† Raichur district in Karnataka has now been split into two  smaller districts. Composite Raichur district refers to these two
smaller districts Raichur and Koppal
Superscript numerals indicate reference nos.
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thought to confer resistance to antituberculosis
drugs49-53. A characteristic  feature of these mutations
is that they are unlinked. Thus, resistance to a drug
is usually not  associated  with resistance to an
unrelated drug.  A  tuberculosis  cavity  usually
contains 107 to 109 bacilli. If mutations causing
resistance to isoniazid occur  in  about  1 in 106
replications of bacteria, and the mutations causing
resistance to rifampicin occur in about 1 in108
replications, the probability  of spontaneous
mutations causing resistance to  both  isoniazid   and
rifampicin  would be 106 x 108 = 1 in 1014.  Given
that  this number of bacilli cannot be found even in
patients  with  extensive  cavitatory pulmonary
tuberculosis, the  chance  of  spontaneous dual
resistance to rifampicin and isoniazid developing is
practically remote49-53. Thus, the fact that mutations
are unlinked forms the scientific basis of
antituberculosis chemotherapy. The primary
mechanism of multiple drug resistance in tuberculosis
is due to perturbations in  the  individual  drug target
genes51,52.  Table II lists the molecular mechanisms
of drug resistance as they are understood today49-53.
Scanty information is available regarding the
molecular basis of drug resistance in India. In studies
published from India54,55,  in addition to the previously
reported mutations,  several novel mutations were
also observed in the rpoB (rifampicin), katG and the
ribosomal binding site of inhA (isoniazid), gyrA and
gyrB (ofloxacin), and rpsL and rrs (streptomycin).
Mani et al56 analysed the mutations in 44 drug-
resistant and six drug-sensitive M. tuberculosis
clinical isolates from various parts of India in the
81-bp rifampicin resistance-determining region
(RRDR) of the rpoB gene by DNA sequencing. Fifty
three mutations of 18 different kinds, 17 point
mutations and one deletion, were observed in 43 of
44 resistant isolates. Three novel mutations and three
new alleles within the RRDR, along with two novel
mutations outside the RRDR, were reported by these
workers56.  These observations suggest that while
certain mutations are widely present, pointing to the
magnitude of the polymorphisms at these loci, others
are not common, suggesting diversity in the
multidrug-resistant M. tuberculosis strains prevalent
in this region.  Further, it was observed that
rifampicin resistance was found to be an important
marker for checking multi-drug resistance in clinical
isolates of M. tuberculosis54.
DIAGNOSIS OF MDR-TB
Conventional methods
Traditionally,  Lowenstein-Jensen (LJ) culture has
been  used  for  drug  sensitivity  testing using    (i)
absolute  concentration  method;  (ii)  the  resistance
ratio  method;  and  (iii)  the  proportions  method16,17.
With the conventional  methods, 6-8 wk time is
required before sensitivity results are known.
In absolute concentration method, the minimal
inhibitory concentration (MIC) of the drug is
Table II. Antituberculosis drugs and the  gene(s) involved in their resistance
Drug Gene(s) involved in drug resistance
Isoniazid Enoyl acp reductase (inhA)
Catalase-peroxidase (katG)
Alkyl hydroperoxide reductase (ahpC)
Oxidative stress regulator (oxyR)
Rifampicin RNA polymerase subunit B (rpoB)
Pyrazinamide Pyrazinamidase  (pncA)
Streptomycin Ribosomal protein subunit 12 (rpsL)
16s ribosomal RNA (rrs)
Aminoglycoside phosphotransferase gene (strA)
Ethambutol Arabinosyl transferase (emb A,B and C)
Fluoroquinolones DNA gyrase (gyr A and  B)
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determined by inoculating the control media and drug
containing media with a carefully controlled
inoculum of M. tuberculosis. Media containing
several sequential two-fold dilutions of each drug are
used. Resistance is indicated by the lowest
concentration of the drug which will inhibit growth
(defined as 20 colonies or more at the end of four
weeks)16,17.   In resistance ratio method, MIC of the
isolate is expressed as a multiple of the MIC of a
standard susceptible strain, determined concurrently,
in order to avoid intra- and inter-laboratory
variations. These two  methods require stringent
control of the inoculum size and hence are not optimal
for direct sensitivity testing from concentrated
clinical specimens. In the proportions  method, the
ratio of the number of colonies growing on drug
containing medium to the number of colonies
growing on drug free medium indicates the
proportion of drug resistant bacilli present in the
bacterial population. Below a certain proportion
called critical proportion, a strain is classified as
susceptible, and above that as resistant16,17.
Modern methods
Radiometric methods have been developed
for rapid drug-susceptibility testing of
M. tuberculosis57-59. In the BACTEC-460 (Becton-
Dickinson) radiometric method, 7H12 medium
containing palmitic acid labelled with radioactive
carbon (14C-palmitic acid) is inoculated. As the
mycobacteria metabolise these fatty acids,
radioactive carbon dioxide (14CO2) is released which
is measured as a marker of bacterial growth.  The
proportions method has been modified by
incorporating the BACTEC technique in place of the
conventional Lowenstein-Jensen  culture. With this
modification,  sensitivity  results will be available
within 10 days57,58.
The mycobacteria growth indicator tube (MGIT)
system (Becton-Dickinson) is a rapid, non-
radioactive method for detection and susceptibility
testing of M. tuberculosis59,60. The MGIT system
relies on an oxygen-sensitive fluorescent compound
contained in a silicone plug at the bottom of the tube
which contains the medium to detect mycobacterial
growth. The medium is inoculated with a sample
containing mycobacteria and  with  subsequent
growth mycobacteria utilise the oxygen and the
compound fluoresces. The fluorescence thus
produced is detected by using a ultraviolet
transilluminator. Studies carried out both with
cultures and direct clinical samples showed
comparable results with the BACTEC and the
proportions method60.
Restriction fragment length polymorphism
(RFLP) patterns used  to  categorise  isolates  of   M.
tuberculosis  and to compare them, has facilitated
the elucidation of molecular epidemiology of TB61.
In this technique, DNA is extracted from the cultured
bacilli. A restriction endonuclease such as PvuII
cleaves the element at base pair 461. Subsequent steps
involve separation of DNA fragments by
electrophoresis on an agarose gel, transfer of the
DNA to a membrane (Southern blotting), followed
by  hybridisation and detection with a labelled DNA
probe. The DNA from each mycobacterial isolate is
depicted as a series of bands on an X-ray film to
create the fingerprint. A banding pattern  reflecting
the number and position of copies of IS6110   (a 1361
base pair insertion sequence) within the
chromosomes is obtained and this depends on the
number of insertion sequences and the distance
between them. As the DNA fingerprints of M.
tuberculosis have been observed not to change during
the development of drug resistance, RFLP analysis
has also been used to track  the spread of drug-
resistant strains61. Recently, Goulding et al62
determined the value of  fluorescent amplified-
fragment length polymorphism (FAFLP) analysis for
genetic analysis of M. tuberculosis and suggested that
FAFLP can be used in conjunction with IS6110 RFLP
typing to further  understand the molecular
epidemiology  of M. tuberculosis.
Ligase  chain  reaction  (LCR) involves the  use
of  an  enzyme DNA ligase which functions to link
two strands of  DNA   together to continue as a double
strand. This can occur only  when the ends are
complementary and match exactly, and this method
facilitates the  detection of  a mismatch of even one
nucleotide63-65.  Luciferase  reporter  assay is a novel
reporter  gene  assay system  for the rapid
determination of drug resistance66-68.  It  is  based on
the gene coding for  luciferase,  an  enzyme  identified
as the light producing system of fireflies. In the
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presence of adenosine triphosphate (ATP), it interacts
with luciferin and emits light. The luciferase gene is
placed into a mycobacteriophage.  Once   this
mycobacteriophage  attaches to  M.tuberculosis, the
phage DNA is injected into it and the viral  genes
are  expressed.  If  M. tuberculosis  is infected  with
luciferase reporter phage and these  organisms are
placed   in  contact   with antituberculosis   drugs,
susceptibility can be tested by correlating the
generation of light  with conventional methods of
testing.  This  technique has  the potential to identify
most strains within 48 h66-68.
FASTPlaqueTB-RIF, a rapid bacteriophage-based
test, to identify rifampicin susceptibility in clinical
strains of M.tuberculosis  after growth in the
BACTEC-460 semi-automated liquid culture system
has also shown potential to rapidly aid in the
diagnosis of MDR-TB69,70.
Polymerase chain reaction (PCR) based
sequencing has often been employed to understand
the genetic mechanisms of drug resistance in
mycobacteria71. This technique allows for detection
of both previously recognised and unrecognised
mutations. The PCR-based  methods  are not readily
applicable for routine identification of drug resistance
mutations because several sequencing reactions need
to be performed for each isolate. However, for targets
such as rpoB, where mutations associated with
rifampicin resistance are concentrated in a very short
segment of the gene, PCR-based sequencing is a
useful technique71.
The Line Probe assay (LiPA; Inno-Genetics NV,
Zwijndrecht, Belgium) has been used for rapid
detection of rifampicin resistance71. LiPA technique
is based on the reverse hybridisation method, and
consists of PCR amplification of a segment of the
rpoB gene followed by denaturation and hybridisation
of the biotinylated PCR amplicons to capture probes
bound to a nitrocellulose strip and detection of the
bound amplicons  producing a colour reaction. The
interpretation of the banding pattern on the strip
allows the  identification of M. tuberculosis complex
and detection of rpoB mutations. DNA microarray
technology used  for mycobacterial species
identification has also been used for rapid detection
of mutations that are associated with resistance to
antituberculosis drugs72,73. However, most  of the
modern diagnostic methods are confined to research
laboratories and are several years away from being
available  for use in the field setting.
Role of multidrug transporters
Multidrug transporters comprise four families of
transmembrane efflux proteins that actively pump out
a broad range of structurally unrelated compounds
from the interior of the cell, using either proton
motive force or ATP supplied energy74. These
proteins are expressed by all organisms ranging from
prokaryotes to higher eukaryotes, including human
cells. They mediate both intrinsic and acquired
resistance to various drugs of a multitude of
organisms such as Pseudomonas sp., Candida sp.,
Plasmodium sp. and cancer cells74. P-glycoprotein is
a human analogue of these multidrug transporters and
is expressed on immune effector cells75. It has been
observed that infection of experimental cell lines by
M. tuberculosis results in increased expression of P-
glycoprotein and decreased accumulation of isoniazid
inside the cells76. Apart from the up regulation of
host cell P-glycoprotein, M. tuberculosis per se
expresses at least three multidrug transporter proteins
Tap, Lfr A and Mmr77-79.  The potential contribution
of these multidrug transporter proteins in the
causation of MDR-TB merits further evaluation.
These transmembrane efflux proteins also appear to
be  novel targets for drug therapy in future.
POTENTIAL CAUSES OF DRUG RESISTANCE
Various factors have been implicated in the
causation of MDR-TB80. These are discussed below:
Genetic factors
Though there is  some  evidence  to  postulate
host genetic  predisposition  as  the  basis  for   the
development of MDR-TB, it has not been
conclusive81-84.  In a recent study from India83, patients
with HLA-DRB1*13 and -DRB1*14 were found to
have two-fold increased risk of developing MDR-TB.
Park et al84 found that susceptibility to MDR-TB in
Korean patients was   strongly associated with HLA-
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DRB1*08032-DQB1*0601 haplotypes. The exact
role of these factors is not known. It is likely that
these loci or the alleles linked with them play a
permissive role in conferring increasing susceptibility
to the development of  MDR-TB.
Factors related to previous antituberculosis
treatment
Incomplete and inadequate treatment: Review  of
published literature strongly suggests  that  the  most
powerful  predictor  of the presence  of  MDR-TB  is
a  history of treatment of tuberculosis. TB patients
in India get treated with DOTS regimens not only
through the Revised National Tuberculosis Control
Programme (RNTCP), but also receive treatment
from private medical practitioners. Irregular,
incomplete,  inadequate treatment is the commonest
mean of acquiring drug  resistant  organisms.
Mahmoudi and Iseman85 observed that among the
35 patients with MDR-TB patients, errors in
management decisions occurred in 28 patients, at an
average of 3.93 errors per patient85. The most
common errors were the addition of a single drug to
a failing regimen, failure to identify preexisting or
acquired drug resistance, initiation of an inadequate
primary regimen, failure to identify and address
noncompliance and inappropriate isoniazid
preventive therapy. Moreover, the group in which
management errors occurred had more extensive
acquired drug resistance compared to the group where
there were no errors 85.
Use of single drug to treat TB is another common
predisposing cause in the Indian setting.  This could
have occurred because of ignorance, use of penicillin/
streptomycin combinations; use of rifampicin for
other diseases, and economic constraints.
Furthermore, there is a problem of using unreliable
combinations with an appreciable  failure rate  such
as thiacetazone/isoniazid as initial treatment. Another
common error in prescription  practice is the “addition
syndrome”.  If another drug is added to the  existing
regimen  when the patient appears to  deteriorate
clinically and  if resistance had developed to the drugs
in use,  adding another  drug  effectively amounts to
monotherapy  with  the  drug.  There is also a risk of
use of unreliable drugs with poor bioavailability
(e.g. ,   rifampicin,  isoniazid, pyrazinamide
combinations).  Use of antituberculosis drugs by
unqualified persons or alternative medicine
practitioners in bizarre regimens for inadequate
periods is an important problem in our country.  Free
availability of antituberculosis drugs over the counter
may contribute to this.
Inadequate treatment compliance: The change- over
from fully supervised sanatorium treatment to
unsupervised domiciliary treatment has  affected
compliance  significantly. Poor compliance with
treatment is also an important factor in the
development of acquired drug resistance. In a study
conducted in south India37, it was observed that only
43 per cent  of the patients receiving short-course
treatment (n=2306) and 35 per cent of those receiving
standard chemotherapy  (n=1051) completed 80 per
cent or more of their treatment37.
Noncompliance with prescribed treatment is often
underestimated by the physician and is difficult to
predict. The drug defaulter, just like placebo reactor
is not a consistent or readily identified person86. In
the west, demographic factors such as age, sex,
marital status, education level and socio-economic
status have not been found to correlate with the degree
of compliance. On the other hand, certain factors such
as psychiatric illness, alcoholism, drug addiction and
homelessness do predict noncompliance86,87. This
may not be entirely true in the Indian context and the
relevance of these factors in the Indian scenario merits
further study.
Considering the changing epidemiological
scenario DOTS is presently being advocated by the
WHO to be the only effective way to control
tuberculosis4,88,89. However, DOTS has not been
adopted universally and the control programmes in
several parts of the world are chaotic80.
Santha et al90 studied the risk factors associated
with default, failure and death among TB patients
treated in a newly implemented DOTS programme
in south India. In this study, 676 patients were
registered during the one year study period. In
multivariate analysis, higher default rates were
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associated with irregular treatment [adjusted odds
ratio (AOR) 4.3; 95 per cent confidence intervals
[(95% CI) 2.5-7.4],  male sex (AOR 3.4; 95%CI 1.5-
8.2), history of previous treatment (AOR 2.8; 95%
CI 1.6-4.9), alcoholism (AOR 2.2; 95%CI 1.3-3.6),
and diagnosis by community survey (AOR 2.1;
95%CI 1.2-3.6). Patients with MDR-TB were more
likely to fail treatment (33 vs. 3%; P<0.001). More
than half of the patients receiving category II
treatment who remained sputum-positive after three
or four months of treatment had MDR-TB, and a large
proportion of these patients failed treatment. Higher
death rates were independently associated with weight
less than 35 kg (AOR 3.8; 95% CI 1.9-7.8) and history
of previous treatment (AOR 3.3; 95% CI 1.5-7.0)90.
Johnson et al91, in a study of 109 culture-positive
pulmonary tuberculosis patients found a high
incidence of drug resistance in previous treatment
defaulters while only four of the 27 new incident cases
had MDR-TB.  The various reasons for default
included travel to different places, symptom relief,
adverse drug reactions and inability to afford
treatment91.
Lack of laboratory diagnostic facilities
Good, reliable  laboratory support is seldom
available in developing nations.  Unfortunately, these
are the areas where  MDR-TB is a major health
hazard. When facilities for culture and sensitivity
testing are not available, therapeutic decisions are
most often made by algorithms or inferences from
previous treatment. Guidelines such as those
published by the WHO are often resorted to choose
the treatment regimen15.
For patients categorised as treatment failure  the
WHO re-treatment regimen consists of three drugs
(isoniazid, rifampicin, and ethambutol) for a period
of eight months, supplemented by pyrazinamide
during the first three months and streptomycin during
the first  two months15. If mycobacterial culture and
in vitro sensitivity testing are not routinely performed,
it is not possible to establish whether these patients
are excreting multidrug-resistant bacilli. If this WHO
re-treatment regimen is administered to treatment
failure patients who actually have MDR-TB
(resistance to rifampicin and isoniazid with or
without resistance to other antituberculosis drugs),
it is evident that during the last five months the patient
will be receiving isoniazid, rifampicin and ethambutol
only and this would amount to “monotherapy” with
ethambutol. Thus, “programmatic approach”  to  the
management of “treatment failure” patients  may fail
in some settings as is evident from the following
reports92,93. The programme of tuberculosis control
using first-line therapy and DOTS was assessed in
467 patients with sputum-positive  tuberculosis in a
prison setting in Baku, Azerbaijan92. Drug resistance
data on  admission were available for 131 patients
and 55 per cent of patients had strains of M.
tuberculosis resistant to two or more drugs. Mortality
during treatment was 11 per cent, and 13 per cent of
patients defaulted. Overall, treatment was successful
in 54 per cent of   patients, and in 71 per cent of
those completing treatment. One hundred and four
patients completed a full treatment regimen and
remained sputum-positive. Resistance to two or more
drugs, a positive sputum result at the end of initial
treatment, cavitary disease, and poor compliance were
independently associated with treatment failure. The
authors concluded that the effectiveness of a DOTS
programme with first-line therapy fell short of the
85 per cent target set by WHO. First-line therapy may
not be sufficient in settings with a high degree of
resistance to antibiotics92.
Similar observations were made in another study
with results of treatment with first-line drugs for
patients enrolled in the WHO and the IUATLD’s
global project on drug-resistance surveillance93.
Patients with tuberculosis in the Dominican Republic,
Hong Kong Special Administrative Region (People’s
Republic of China), Italy, Ivanovo Oblast (Russian
Federation), the Republic of Korea, and Peru were
studied in this retrospective cohort study.  Of the 6402
culture-positive cases evaluated, 5526 (86%) were
new cases and 876 (14%) were re-treatment cases. A
total of 1148 (20.8%) new and 390 (44.5%) re-
treatment cases were drug resistant, including 184
and 169 cases of MDR-TB, respectively. Of the new
cases, 4585 (83%) were treated successfully, 138
(2%) died, and 151  (3%) experienced short-course
chemotherapy failure. Overall, treatment failure and
mortality were higher among new MDR-TB cases
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than among new susceptible cases.  Even in
settings using 100 per cent direct observation,
cases with multidrug resistance had a significantly
higher failure rate than those who were susceptible
[10 vs 0.7%; relative risk (RR), 16.9; 95% CI, 6.6-
42.7; P<.001].  The data suggest that standard
short-course chemotherapy, based on first-line
drugs, is an inadequate treatment for some patients
with drug-resistant TB93. Although the DOTS
strategy is the basis of good TB control, the
strategy should be modified in some settings to
identify drug-resistant cases sooner, and to make
use of second-line drugs in appropriate treatment
regimens94-98.
PREDICTORS FOR THE DEVELOPMENT OF
MDR-TB
Certain factors have been documented to be
associated with the development of MDR-TB. In
an analysis to identify determinants of drug-
resistant TB, population-based representative data
on new and previously treated patients with TB
collected within an international drug resistance
surveillance network were studied99. Of the 9,615
patients, 85.5 per cent were new cases and 14.5
per cent were previously treated cases. Compared
with new cases, patients who received treatment
in the past were more likely to have resistance to
antituberculosis drugs. An approximately linear
increase was observed in the likelihood of having
MDR-TB as the total time of prior antituberculosis
t reatment  measured in  months  increased.
Mult ivar ia te  analysis  revealed that   pr ior
antituberculosis  treatment but not HIV positivity,
was associated with  MDR-TB99.  In a study from
Saudi  Arabia 100,  previous  his tory  of
antituberculosis treatment and young age were
found to be risk factors associated with the
development of MDR-TB. In a study from New
Delhi 83,  the  presence of  pas t  h is tory  of
tuberculosis, poor compliance to treatment, low
socioeconomic status and body mass index (BMI,
kg/m2) <18 kg/m2  were independent contributors to
the risk of developing MDR-TB. In most of the
published studies, previous history of tuberculosis
and past history of antituberculosis treatment have
been implicated in the causation of MDR-TB83,99-103.
MANAGEMENT
In the early reports of outbreaks of MDR-TB in
HIV co-infected patients in hospitals and prisons, the
mortality rate was very high ranging form 72  to 89
per cent104-108. However, subsequent studies have
documented decreased  mortality and improvement
in clinical outcome for HIV-seropositive patients with
MDR-TB who were started on at least two drugs with
in vitro susceptibility against the MDR-TB
isolate96,109,110. Even in HIV seronegative patients,
treatment of MDR-TB has been difficult and may
only give response rates of the order of 50 per cent
with a high mortality rate with  persistent positive
cultures95-97,111,112.
In resource-poor nations, the treatment of MDR-
TB has been considered  to be very expensive  and
available only at referral centres. In a recently
published study113,  results of community-based out-
patient treatment  of MDR-TB were reported form
Peru.  While the results of susceptibility testing were
pending, the patients were treated empirically under
direct observation with regimens containing at least
five drugs to which the strains were likely to be
susceptible. The definitive regimens, determined on
the basis of the results of drug susceptibility,
contained a minimum of five drugs and lasted for at
least 18 months.  Of the  66 patients who completed
four or more months of therapy, 55 (83%) were
probably cured (defined as at least 12 months of
consecutive negative cultures during therapy). Five
of these 66 patients (8%) died while receiving
treatment. Only one patient continued to have positive
cultures after six months of treatment. Low
haematocrit [hazard ratio (HR) 4.09; 95% CI, 1.35
to 12.36] and a low BMI (kg/m2) (HR, 3.23; 95% CI,
0.90 to 11.53) were found to be the predictors of the
time to treatment failure or death. These observations
suggest that community-based out-patient treatment
of MDR-TB has the potential to yield high cure rates
even in resource-poor settings113.
Sparse data are available from published literature
regarding the treatment of patients with MDR-TB
from India. In a study from New Delhi, additional
administration of oral ofloxacin was found to be
effective and safe for the treatment of  MDR-TB10.
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In an uncontrolled study from Manipal,  Karnataka114,
pefloxacin, with its low cost and high safety profile
was considered to be a useful companion drug in
selected cases. A prospective uncontrolled study from
New Delhi115 reported that sparfloxacin, in
combination with kanamycin (for the initial 3 to 4
months) and ethionamide treatment was useful  in
achieving sputum conversion, clinical and
radiological improvement in nine patients with
pulmonary tuberculosis who had received adequate
antituberculosis treatment with first-line drugs,
including supervised category II treatment regimen
as per WHO guidelines for five months, and were
still sputum smear positive. In a study from Vellore,
Tamil Nadu116, combination therapy containing
ofloxacin was useful in achieving sputum conversion
in 26 of 49 (53%) patients and culture conversion
occurred in 16 of 26 (61.5%) patients. Clinical and
radiological response was noted in 31 (56%) and 13
(32.5%) out of 40 patients respectively.
Prognostic markers
Park et al96 reported that extra-pulmonary
involvement was a risk factor for shorter survival,
while a cavitary lesion on initial chest film and
institution of appropriate treatment were positive
predictors of survival in patients with MDR-TB. In a
recently published study  from the United
Kingdom112, overall median survival time  was 1379
days (95% CI 1336 to 2515). Median survival time
was 858 days (95% CI 530 to 2515) in
immunocompromised individuals and 1554 (95% CI
1336 to 2066) days in immunocompetent persons.
Median survival in patients treated with three drugs
to which the bacterium was susceptible on in vitro
testing was 2066 days (95% CI 1336 to 2515),
whereas, in those not so treated survival was 599 days
(95% CI 190 to 969). Immunocompromised status,
failure to culture the bacterium in 30 days or to apply
appropriate treatment with three drugs to which the
organism is susceptible, and age were significant
factors in mortality. An immunocompromised patient
was nearly nine times more likely to die, while
application of appropriate treatment reduced the risk.
Increasing age was associated with increasing risk
of death (risk ratio 2.079; 95% CI 1.269 to 3.402)
suggesting that, for every 10 yr increase in age the
risk almost doubled112.  In a study from France117, in
patients with MDR-TB, HIV-coinfection, treatment
with less than two active drugs, and knowledge
regarding the multidrug-resistant status at the time
of diagnosis were found to be associated with a poor
outcome. In study from Turkey118, older age and
history of previous treatment with a larger number
of drugs were found to be associated with a poor
outcome.
Guidelines for the management of patients with
MDR-TB
When MDR-TB is suspected on the basis of
history or epidemiological information, the patient’s
sputum  must be subjected to culture and
antituberculosis drug sensitivity testing and the WHO
re-treatment regimen15  or the empirical regimens
employing second-line reserve drugs  (Tables III and
IV) suggested by the American Thoracic Society,
Centers for Disease Control and Prevention and the
Infectious Diseases Society of America (ATS/CDC/
IDSA)119  must be initiated pending sputum culture
report. Further therapy is guided by the culture and
sensitivity report. These guidelines clearly mention
that a single drug should never be added to a failing
regimen. Furthermore, when initiating treatment, at
least three previously unused drugs must be employed
to which there is in vitro susceptibility15,119.
When susceptibility testing reports are available
and there is resistance to isoniazid and rifampicin
(with or without resistance to streptomycin) during
the initial phase, a combination of ethionamide,
fluoroquinolone, another bacteriostatic drug such as
ethambutol, pyrazinamide and aminoglycoside
(kanamycin, amikacin, or capreomycin) are used for
three months or until sputum conversion. During the
continuation phase, ethionamide, fluoroquinolone,
another bacteriostatic drug (ethambutol) should be
used for at least 18 months after smear
conversion15,119(Table IV). If there is resistance to
isoniazid, rifampicin and ethambutol (with or without
resistance to streptomycin) during the initial phase,
a combination of  ethionamide, fluoroquinolone and
another bacteriostatic drug such as cycloserine or
PAS, pyrazinamide, and aminoglycoside (kanamycin,
amikacin, or capreomycin) are used for three months
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Table III. Daily dosage and toxicity status of second-line antituberculosis drugs
Drug Daily dosage Toxicity
dose (range)
Aminoglycosides
Streptomycin 15 mg/kg  (750-1000 mg) Medium
Kanamycin 15 mg/kg (750-1000 mg) Medium
Amikacin 15 mg/kg (750-1000 mg) Medium
Capreomycin 15 mg/kg  (750-1000 mg) Medium
Thioamides
Ethionamide 10-20 mg/kg (500-750 mg) Medium
Prothionamide 10-20 mg/kg (500-750 mg) Medium
Pyrazinamide 20-30 mg/kg (1200-1600 mg) Low
Ofloxacin 7.5-15 mg/kg (600- 800 mg) Low
Levofloxacin 500-1000 mg Low
Ethambutol 15-20 mg/kg (1000-1200 mg) Low
Cycloserine 10-20 mg/kg (500-750 mg) High
Para-aminosalicylic acid 10-12 g Low
Source: Refs. 15, 119
or until sputum conversion. During the continuation
phase, ethionamide, ofloxacin, another bacteriostatic
drug (cycloserine or PAS) should be used for at least
18 months after smear conversion15,119.
The recently published ATS/CDC/IDSA119
guidelines suggest that among the fluoroquinolones,
levofloxacin is most suited for the treatment of MDR-
TB given its good safety profile with long-term use.
These observations need to be confirmed in
prospective studies with a large sample size.
When administering antituberculosis drugs by the
parenteral route, proper precautions must be taken.
This is particularly relevant  in countries like India
where, disposable  syringes are  not always available
for giving the injections  and  the use of improperly
sterilized needles would be a health hazard  especially
in patients with HIV infection and AIDS.
Second-line drugs are very difficult to obtain in
small towns and rural areas in India. Therefore,
reliable supply of drugs is a difficult problem.
Moreover, there is a wide variation in the price range
between different pharmaceutical brands. Reliable
pharmacokinetic data regarding bioavailability of
most of these formulations are not available and there
is no assurance that the most expensive brand names
have the best bioavailability profile. Even
considering the cheapest brand names available, the
cost of drug treatment alone is much beyond the
means of the average Indian patient. Therefore, long-
term compliance is not very good. All these factors
constitute   significant therapeutic challenges for the
clinicians treating MDR-TB in the field setting.
Population migration due to poverty to seek better
job opportunities, natural disasters, wars, political
instability and regional conflicts also create mobile
populations. These factors make treatment of MDR-
TB difficult120,121.
DOTS-plus strategy
DOTS is a key ingredient in the tuberculosis
control strategy. In populations where MDR-TB is
endemic, the outcome of the standard short-course
regimen remains uncertain. Unacceptable failure rates
have been reported and resistance to additional agents
may be induced80. As a consequence, there have been
calls for well-functioning DOTS programmes to
provide additional services in areas with high rates
of MDR-TB. These “DOTS-plus for MDR-TB
programmes”80,94,121 may need to modify all five
elements of the DOTS strategy:  (i) the treatment may
need to be individualized rather than standardised;
(ii) laboratory services may need to provide facilities
for on-site culture and antibiotic susceptibility
testing; (iii) reliable supplies of a wide range of
SHARMA & MOHAN: MDR-TB
366 INDIAN J MED RES, OCTOBER 2004
expensive second-line agents; (iv) operational studies
would be required to determine the indications; and
(v) financial and technical support from international
organizations and Western governments would be
needed in addition to that obtained from local
governments. WHO has established a Working Group
on DOTS-Plus for MDR-TB, to develop policy
guidelines for the management of MDR-TB and to
develop protocols for pilot projects intended to assess
the feasibility of  MDR-TB management under
programme conditions. The WHO has also
established a unique partnership known as the Green
Light Committee (GLC) in an attempt to promote
access to and rational use of second-line
antituberculosis drugs for the treatment of MDR-
TB123-125. If  DOTS-plus programmes are established,
they may prove beneficial not only for patients with
MDR-TB but for all patients with tuberculosis.
Monitoring response to treatment
Patients receiving treatment for MDR-TB should
be closely followed up. Clinical (e.g., fever, cough,
sputum production, weight gain), radiological (e.g.,
chest radiograph) , laboratory (erythrocyte
sedimentation rate) and microbiological (e.g., sputum
smear and culture) parameters should be frequently
reviewed to assess the response to treatment. In
addition, considerable attention must be focussed on
monitoring the adverse drug reactions which often
develop with the second-line antituberculosis drugs.
A detailed description of these adverse drug reactions
is beyond the scope of this review. Majority of the
patients who respond to treatment begin to show
favourable signs of improvement by about  four to
six weeks following initiation of treatment.  Failure
to show positive trend  may alert the clinician to resort
to other measures outlined below.
Newer antituberculosis drugs
Currently available second-line drugs used to treat
MDR-TB (Table III) are four to ten times more likely
to fail than standard therapy for  drug-susceptible
tuberculosis94-98.  After the introduction of rifampicin,
no worthwhile antituberculosis drug with new
mechanism(s) of action has been developed in over
thirty years. Moreover, no new drugs that might be
Table IV. Suggested treatment for patients with MDR-TB
Resistance pattern Initial phase Continuation phase
Drugs Minimum duration Drugs Minimum duration
(months) (months)
Resistance to Aminoglycoside 3 Ofloxacin or 18-24
isoniazid and levofloxacin
rifampicin with Ofloxacin or
or without levofloxacin Ethambutol
resistance to Ethionamide
streptomycin Pyrazinamide
Ethambutol
Ethionamide
Resistance to Aminoglycoside 3 Ofloxacin or 18-24
isoniazid, levofloxacin,
rifampicin and Ofloxacin or
ethmbutol  with levofloxacin Ethionamide
or without Cycloserine
resistance to Pyrazinamide
streptomycin Ethionamide
Cycloserine
During the ontinuation phase antituberculosis drugs are administered for a period of at least 18 months after sputum conversion
Source: Refs. 15,119
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effective in treatment of MDR-TB are currently
undergoing clinical trials. It appears that effective
new drugs for tuberculosis are at least a decade
away98. Recently, a series of compounds containing
a nitroimidazopyran nucleus that possess
antituberculosis activity have been described122. After
activation by a mechanism dependent on M.
tuberculosis F420 cofactor, nitroimidazopyrans
inhibited the synthesis of protein and cell wall lipid.
In contrast to current antituberculosis drugs,
nitroimidazopyrans exhibited bactericidal activity
against both replicating and static bacilli. Lead
compound PA-824 showed potent bactericidal
activity against multidrug-resistant M. tuberculosis
and promising oral activity in animal infection
models. It is being hoped that these
nitroimidazopyrans offer the practical qualities of a
small molecule with the potential for the treatment
of tuberculosis122.
Surgery
Various surgical procedures performed for patients
with MDR-TB have ranged from segmental resection
to pleuro-pneumonectomy126-130.  Based on the
experience reported in the literature about surgery
for MDR-TB, it can be concluded that the operation
can be performed  with a low mortality (<3%).
However, the complication rates are high with
bronchopleural fistula (BPF) and  empyema being
the major complications. Sputum positivity at the
time of surgery, previous chest irradiation, prior
pulmonary resection and extensive lung destruction
with polymicrobial parenchymal contamination are
the major factors affecting morbidity and mortality.
Over 90 per cent of the patients achieve sputum-
negative status post-operatively. Although operation
related mortality is less than three per cent,  deaths
due to all causes occur in about 14 per cent patients.
Even this compares favourably with over 22 per cent
mortality due to TB in a similar group of patients
treated medically126. More liberal use of muscle flaps
to reinforce the bronchial stump and fill the residual
space has helped significantly in reducing the rates
of BPF, air leaks  and residual space problems. These
must  be used in patients with positive sputum, when
residual post-lobectomy space is anticipated, when
BPF  already exists pre-operatively or when extensive
polymicrobial contamination is present.
Thus, resectional surgery is currently
recommended for MDR-TB patients whose prognosis
with medical treatment is poor. Indications for
surgery in patients with MDR-TB include: (i)
persistence of culture-positive MDR-TB despite
extended drug retreatment; and/or (ii) extensive
patterns of drug resistance that are  associated with
treatment failure or additional resistance; and/or
(iii) local cavitary, necrotic/destructive  disease in a
lobe or region of the lung that was amenable to
resection without producing respiratory insufficiency
and/or severe pulmonary hypertension.  It should be
performed after minimum of three months of
intensive chemotherapeutic regimen, achieving
sputum-negative status, if possible. The operative
risks are acceptable and the long-term survival is
much improved than that with continued medical
treatment alone. However, for this to be achieved,
the chemotherapeutic regimen  needs to continue for
prolonged periods after surgery also, probably for
well over a year, otherwise  recrudescence  of the
disease with poor survival is a real possibility.
Nutritional enhancement
Tuberculosis is a wasting disease. The degree of
cachexia is most profound when MDR-TB occurs in
patients with HIV-infection/AIDS131. While the
mechanisms involved in weight loss are not well
known, current evidence points to tumour necrosis
factor-α (TNF-α) to be the cytokine responsible for
this phenomenon.  TNF-α, in addition to inducing
immunopathological effects such as tissue necrosis
and fever,  is also thought to induce the catabolic
response132. Further, several second-line drugs used
to treat MDR-TB such as PAS, fluoroquinolones
cause significant anorexia, nausea, vomiting and
diarrhoea interfering with food intake, further
compromising the cachectic state. Therefore,
nutritional support is a key factor in the care of
patients with MDR-TB, especially those undergoing
major lung surgery. Though definitive evidence is
not yet available, it is generally believed that
malnourished patients are at a greater risk of
developing post-operative complications126.
Nutritional assessment and regular monitoring of
the nutritional state by a dietician are essential for
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the successful management of MDR-TB patients and
should be an essential part of such programmes.
When the routine measures are not able to improve
the nutritional status and induce weight gain,
nasogastric feeding  may be employed to supplement
the diet. When the patients are very sick and have
severe nutritional deficit,  feeding gastrostomy/
jejunostomy may have to be performed.
Immunotherapy
Ever since the early attempts by Robert Koch,
several workers have attempted to modify the immune
system of patients with tuberculosis to facilitate
cure133,134. The measure employed in the earlier days
included heliotherapy, dietary supplementation
including milk and cod-liver oil. It is likely that these
interventions acted through 1,25 (OH)2 D3, which is
now recognised to have significant effects on T-
lymphocyte and macrophage  function. Agents with
potential for immunotherapy are detailed below.
Mycobacterium vaccae vaccination: Transiently
favourable results were observed when
immunoenhancement using M. vaccae vaccination
was used to treat drug-resistant tuberculosis patients
who failed chemotherapy133,134. It was postulated that
M.vaccae redirected the host’s cellular response from
a Th-2  dominant to a Th-1 dominant  pathway leading
to less tissue destruction and more effective inhibition
of mycobacterial replication133.  However, subsequent
reports from randomised controlled trials have not
confirmed these observations135.
Cytokine therapy: With further understanding  of the
molecular pathogenetic mechanisms of  tuberculosis,
several attempts have been made to try cytokines in
the treatment of MDR-TB. Recent data, however,
suggest that interferon-γ (IFN-γ )  and interferon-α
(IFN-α) may improve disease evolution in subjects
affected with pulmonary tuberculosis caused by
multidrug-resistant (IFN-γ ) and sensitive (IFN-α)
strains. The mechanisms involved are not known,
even though it has been reported that IFN-gamma-
secreting CD4+ Th cells may possess antituberculosis
effects. In addition, IFN-a can induce IFN-γ secretion
by CD4+ Th cells, and both types of IFN may
stimulate macrophage activities133.
Aerosolised IFN-γ   (500 µg, thrice weekly) has been
found to produce transient, but  clinically encouraging
responses in patients with MDR-TB in an open-label
trial136. The observed benefits included unsustained
sputum smear conversion to negative, delayed growth
of cultures and shrinkage of cavities. Granulocyte-
macrophage colony-stimulating factor (GM-CSF) has
been used  simultaneously with IFN-γ in the successful
treatment of a patient with refractory central nervous
system  MDR-TB137.
Giosue  et al138, studied the usefulness of aerosolised
IFN-α in the treatment of MDR-TB. In this study,  seven
patients who were non-responders to a second-line
antituberculosis treatment after six months of directly
observed treatment were given aerosolised  IFN-α  (3
MU, three times a week)  for two months as adjunctive
therapy. A transient decrease in the colony number per
culture was observed. Preliminary data suggest that
aerosolized IFN-α may be a promising adjunctive
therapy for patients with MDR-TB. Optimal doses and
schedules, however, require further studies.
Interleukin-2 (IL-2) has been used in the treatment
of lepromatous leprosy and is believed  to act  by
enhancing IFN-γ production. By the same analogy, IL-
2 may be useful in the treatment of MDR-TB. Johnson
et al139 reported the usefulness of low-dose recombinant
human interleukin 2 (rhuIL-2) adjunctive
immunotherapy in MDR-TB patients. In this study
MDR-TB patients on best available antituberculosis
chemotherapy also received rhuIL-2 for 30 consecutive
days (daily therapy), or for five days followed by a nine-
day rest, for three cycles (pulse therapy). Placebo control
patients received diluent. The cumulative total dose of
rhuIL-2 given to each patient in either rhuIL-2 treatment
group was the same. Patient immunologic,
microbiologic, and radiologic responses were compared.
The three treatment schedules induced different results.
Immuneactivation was documented in patients receiving
daily rhuIL-2 therapy. Numbers of CD25+ and CD56+
cells in the peripheral blood were increased in these
patients, but not in patients receiving pulse rhuIL-2 or
placebo. In addition, 62 per cent patients receiving daily
rhuIL-2 demonstrated reduced or cleared sputum
bacterial load while only 28 per cent pulse rhuIL-2
treated and 25 per cent controls showed bacillary
clearance. Chest radiographs of  58 per cent patients
369
receiving daily rhuIL-2 indicated significant
improvement over six weeks. Only 22 per cent pulse
rhuIL-2-treated patients and 42 per cent placebo controls
showed radiologic improvement. The authors concluded
that  daily low dose rhuIL-2 adjunctive treatment
stimulates immuneactivation and may enhance the
antimicrobial response in MDR-TB.
Other Agents
Several agents have evoked interest as potential
adjunctive treatment for patients with MDR-TB. Though
very little information is available regarding their clinical
usefulness, they are described here considering their
therapeutic potential. Thalidomide48,140 and
pentoxifylline141,142 have been shown to combat the
excessive effects from TNF-α.  These may be useful in
limiting  the wasting associated with MDR-TB.  Other
agents which have occasionally been considered include,
levamisole143,144, transfer factor145, inhibitors of
transforming growth factor-β (TGF-β)146, interleukin-
12 (IL-12)133, interferon-α (IFN-α) and imiquimod an
oral agent which stimulates the production of
IFN-α147.  Though there have been anecdotal reports of
their usefulness, further studies are required to clarify
their role.
Prevention of  nosocomial transmission of MDR-
TB
As MDR-TB poses a significant risk to health  care
workers, doctors  and other patients, the CDC in
Atlanta have made recommendations to try to prevent
such  nosocomial  transmission148.  These include
isolation  in a single room with negative pressure
relative  to  the outside with six air exchanges per
hour, the room  to be exhausted to the outside;
consideration of ultraviolet lamps or particulate filters
to supplement ventilation; use  of  disposable
particulate  respirators  for   persons  entering the
room and during cough inducing procedures.
Preventive chemotherapy for contacts to MDR-
TB cases and treatment of latent multidrug-
resistant tuberculosis infection
For  contacts  thought  to  be  infected  with
M.  tuberculosis  resistant to both isoniazid and
rifampicin,  no  satisfactory chemoprophylaxis is
available. There is no consensus regarding the choice
of the drug(s) and the  duration of treatment.  The
CDC has put forth guidelines for the management of
persons exposed to multidrug-resistant
tuberculosis149. The guidelines recommended that the
likelihood that (i) the contact is newly infected;
(ii) the infecting strain  is multidrug-resistant; and
(iii) the contact will develop active tuberculosis
should be considered. The CDC recommendations149
also stress the importance of obtaining drug
susceptibility results from the isolate of the presumed
source case and the use of more than one drug, since
the efficacy with drugs other than isoniazid has not
been demonstrated in large trials. Patients with risk
factors for progression to active disease warrant
treatment, although immunocompetent individuals
may be observed closely without therapy for at least
six months. The two suggested regimens for MDR-
TB preventive therapy are149: (i)  pyrazinamide (25
to 30 mg/kg daily) plus ethambutol (15 to 25 mg/kg
daily), or  (ii) pyrazinamide (25 to 30 mg/kg daily)
plus a quinolone with antituberculosis activity (e.g.,
levofloxacin or ofloxacin). The recommended
duration of therapy is 12 months for those with
underlying immunosuppression and at least six
months for all others. All patients should be closely
followed for at least two years, and a low threshold
for referral to a centre with experience in managing
MDR-TB should be maintained.
It has been observed that prophylaxis with
pyrazinamide and levofloxacin in solid organ transplant
recipients possibly exposed to MDR-TB was associated
with limited tolerability due to the high frequency of
adverse events150.  Very little is known regarding the
usefulness of  pyrazinamide and levofloxacin  in the
treatment of multidrug-resistant latent tuberculosis
infection.  In a study from Canada151, this combination
was found to be poorly tolerated regimen as several
patients developed severe adverse drug reactions.  These
issues merit further studies.
In conclusion, treatment of MDR-TB is a
challenge which should be undertaken by experienced
clinicians at centres equipped with  reliable laboratory
service for mycobacterial culture and  in vitro
sensitivity testing. Judicious use of second-line drugs,
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supervised individualised treatment, focussed
clinical, radiological and bacteriological follow-up,
judicious use of surgery at the appropriate juncture
are key factors in the successful management of these
patients.  In certain areas, currently available
programme approach may not be adequate and
innovative approaches such as DOTS-plus may have
to be employed to effectively control MDR-TB.
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